Introduction {#S1}
============

*Escherichia coli* is the main cause of bloodstream infections (BSIs) and in recent years there has been a very significant increase in the number of infections caused by multidrug-resistant isolates, and especially by extended-spectrum β-lactamase-producing *E. coli* (ESBL-EC) ([@B51]; [@B14]; [@B52]). ESBL production in *E. coli* has increased due mainly to the spread of CTX-M enzymes. The high-risk clones have played a very important role in the current pandemic spread, especially the ST131 clone associated with the CTX-M-15 enzyme ([@B39]; [@B8]; [@B42]; [@B1]; [@B2]; [@B11]; [@B28]; [@B23]; [@B25]; [@B46]; [@B33]).

The majority of ST131 isolates belong to the O25b:H4 serotype, subclone *H*30, clonotype CH40-30 and clade C. The *H*30Rx (clade C2) subset often carries *bla*~CTX--M--15~, whereas *H*30R-M27 (clade C1-M27) subset is positive for *bla*~CTX--M--27~ and *H*30R-nM27 (clade C1-nM27) subset is often positive for *bla*~CTX--M--14~. However, there are other two ST131 subclones less frequently expanded: *H*22 (clonotype CH40-22, clade B) and *H*41 (clonotype CH40-41, clade A). Isolates of subclone *H*41 usually belong to serotype O16:H5 ([@B44]; [@B40]; [@B41]; [@B30],[@B29]; [@B19]). Generally, clades A and B show fluoroquinolone (FQ) susceptibility and rarely carry ESBL plasmids, while most isolates of clade C are FQ-resistant. Clade B evolved into clade C by acquisition of several prophages, genomic islands, the *fimH*30 allele and mutations within *gyrA a*nd *parC* genes, mainly during the late 1980s ([@B3]; [@B32]; [@B49]; [@B43]). In addition, considering the content of virulence genes, ST131 isolates can be classified into 12 virotypes (A to F) ([@B6]; [@B12]; [@B35]).

Currently, few data are available on molecular epidemiology of bacteraemia caused by ST131 and non-ST131 clones of ESBL-EC, especially in Europe ([@B45]; [@B20]; [@B13]; [@B34]; [@B46]). Thus, the aim of the present study was to examine the prevalence and determine the molecular characteristics of ESBL-EC causing bacteraemia in a Spanish Hospital over a 12-year period (2000--2011).

Materials and Methods {#S2}
=====================

*E. coli* Bloodstream Isolates {#S2.SS1}
------------------------------

The present study included 2,427 non-duplicate, clinically relevant *E. coli* isolates recovered from blood of patients at Hospital Universitario Lucus Augusti (HULA) (formely Complejo Hospitalario Xeral-Calde) between January 2000 and December 2011. All available isolates from that time period were analyzed. HULA is a university hospital with 740 beds, which serves an urban and rural population of approximately 265,000 inhabitants in Lugo, Spain. Ethics approval was not required according to national and institutional guidelines.

Antibiotic Susceptibility Testing and ESBL Typing {#S2.SS2}
-------------------------------------------------

ESBL production was detected by the double disk synergy test ([@B21]). The type of ESBL was established by PCR and sequencing using the TEM-, SHV-, CTX-M-1, and CTX-M-9 group-specific primers ([@B27]; [@B7]).

Phylogenetic Grouping, MLST, CH Typing, and Identification of *H*30Rx Subclone {#S2.SS3}
------------------------------------------------------------------------------

The determination of the phylogenetic groups (A, B1, B2, C, D, E, F) was carried out by the protocol of [@B9]. The sequence types (STs) were established following the multilocus sequence typing (MLST) scheme of Achtman^[1](#footnote1){ref-type="fn"}^ ([@B55]). Clonotype identification was determined by *fumC* and *fimH* (CH) sequencing ([@B54]; [@B50]). The *H*30Rx subclone was established by PCR detection of a specific SNP (G723A) of *ybbW* gene ([@B2]).

O and H Typing {#S2.SS4}
--------------

The serotyping was carried out using all available O (O1 to O181) and H (H1 to H56) antisera ([@B18]). Isolates that did not react with any antisera were designated as ONT or HNT (NT, non-typeable) and those non motile were denoted as HNM. The O25b subtype was determined by PCR ([@B10]).

Virulence Genotyping {#S2.SS5}
--------------------

Virulence genes were screened by PCR as documented previously ([@B12]), using specific primers ([Supplementary Table S1](#TS1){ref-type="supplementary-material"}). The virulence gene score was the number of extraintestinal virulence-associated genes detected. Isolates were defined presumptively as extraintestinal pathogenic *E. coli* (ExPEC) ([@B22]) if positive for ≥2 of 5 markers, including *papAH* and/or *papC*, *sfa/focDE*, *afa/draBC*, *kpsM II*, and *iutA*, and as uropathogenic *E. coli* (UPEC) ([@B48]) if positive for ≥3 of 4 markers, including *chuA*, *fyuA*, *vat*, and *yfcV*. The virotypes A to F of the ST131 isolates was assigned according to the scheme developed by [@B12].

Pulsed Field Gel Electrophoresis (PFGE) {#S2.SS6}
---------------------------------------

*XbaI*-PFGE profiles were determined as previously described ([@B37], [@B36]) and imported into BioNumerics (Applied Maths, Sint-Martens-Latem, Belgium) and clustered using the UPGMA algorithm and applying Dice coefficient and 1% tolerance.

Statistical Analysis {#S2.SS7}
--------------------

All the *P*-values were calculated using the Fisher's exact test, except for the comparison of the means that was performed using the test one-way ANOVA test. *P*-values \<0.05 were considered statistically significant.

Results {#S3}
=======

Prevalence of ESBL-Producing *E. coli* (ESBL-EC) {#S3.SS1}
------------------------------------------------

During 2000--2011, 2,427 *E. coli* bloodstream isolates were analyzed, of which 96 (4.0%) exhibited ESBL production. The number of ESBL-EC isolates increased from 1.0% (8/827) during 2000--2005 to 5.5% (88/1,600) during 2006--2011 (*P* \< 0.001) ([Figure 1](#F1){ref-type="fig"}, [Table 1](#T1){ref-type="table"}, and [Supplementary Table S2](#TS2){ref-type="supplementary-material"}).

![Prevalence of extended-spectrum β-lactamase-producing *E. coli* (ESBL-EC) and ESBL-EC ST131 isolates. A total 2,427 *E. coli* bloodstream isolates were analyzed, of which 96 (4.0%) exhibited ESBL production. A total of 41 ESBL-EC ST131 isolates were identified and 35 of them belonged to the *H*30Rx subclone.](fmicb-10-01530-g001){#F1}

###### 

Prevalence, serotypes, phylogenetic groups, STs, and clonotypes of extended-spectrum β-lactamase-producing *E. coli* (ESBL-EC) bloodstream isolates.

  **Year**    **Number of *E. coli* isolates**   **Number of ESBL isolates (%)**   **Type of ESBL (number of isolates)**   **Serotypes, phylogenetic groups, sequence types, and clonotypes (number of isolates)^a^**
  ----------- ---------------------------------- --------------------------------- --------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  2000        142                                0                                                                         
  2001        120                                1 (0.8%)                          CTX-M-14 (1)                            O2:H5-B2-ST352-CH96-9 (1)
  2002        93                                 0                                                                         
  2003        90                                 1 (1.1%)                          CTX-M-14 (1)                            O15:H1-E-ST393-CH106-54 (1)
  2004        199                                3 (1.5%)                          CTX-M-14 (1)                            O105:H21-B1-ST359-CH41-35 (1)
                                                                                   CTX-M-9 (1)                             O144:HNM-B1-ST602-CH19-86 (1)
                                                                                   CTX-M-1 (1)                             O15:HNM-E-ST362-CH100-96 (1)
  2005        183                                3 (1.6%)                          CTX-M-32 (2)                            O25a:H25-B1-ST359-CH41-55 (1); O25a:HNM-F-ST648-CH4-58 (1)
                                                                                   CTX-M-14 (1)                            O8:HNT-A-ST48-CH11-0 (1)
  2006        190                                8 (4.2%)                          CTX-M-15 (2)                            **O25b:H4-B2-ST131-CH40-30 (2)**
                                                                                   CTX-M-14 (5)                            O8:H7-B1-ST1642-CH4-31 (1); O23:HNM-B1-ST453-CH6-31 (1); **O25b:H4-B2-ST131-CH40-negative (1)**; O102:H6-E-ST405-CH37-27 (1); O153:H34-F-ST354-CH88-58 (1)
                                                                                   CTX-M-32 (1)                            O2:H4-B2-ST95-CH38-27 (1)
  2007        231                                8 (3.5%)                          CTX-M-15 (5)                            **O25b:H4-B2-ST131-CH40-30 (5)**
                                                                                   CTX-M-14 (1)                            ONT:H4-A-NEW ST^b^-CH11-25 (1)
                                                                                   CTX-M-9 (1)                             ONT:H10-B1-ST711-CH6-289 (1)
                                                                                   CTX-M-1 (1)                             O8:HNT-B1-ST345-CH4-31 (1)
  2008        276                                15 (5.4%)                         CTX-M-15 (6)                            O20:H9-C-ST410-CH4-24 (1); O20:H30-B1-ST156-CH29-38 (1); **O25b:H4-B2-ST131-CH40-30 (4)**
                                                                                   CTX-M-14 (7)                            ONT:HNM-B1-ST58-CH4-32 (1); ONT:H25-B1-ST58-CH4-32 (1); ONT:HNM-C-ST23-CH4-35 (1); ONT:H51-B1-ST359-CH41-35 (1); **ONT:H5-B2-ST131-CH40-41 (1)**; O1:HNM-F-ST354-CH88-58 (1); ONT:H18-D-ST69-CH35-27 (1)
                                                                                   CTX-M-9 (1)                             **O25b:H4-B2-ST131-CH40-22 (1)**
                                                                                   CTX-M-1 (1)                             ONT:H16-B1-ST2602-CH95-38 (1)
  2009        289                                14 (4.8%)                         CTX-M-15 (10)                           **O25b:H4-B2-ST131-CH40-30 (10)**
                                                                                   CTX-M-14 (3)                            O15:H1-E-ST393-CH106-54 (3)
                                                                                   CTX-M-32 (1)                            O101:H10-A-ST10-CH11-54 (1)
  2010        301                                17 (5.6%)                         CTX-M-15 (6)                            **O25b:H4-B2-ST131-CH40-30 (3)**; O8:H6-E-ST405-CH37-27 (1); O130:H6-E-ST405-CH37-27 (1); ONT:H6-E-ST405-CH37-27 (1)
                                                                                   CTX-M-14 (8)                            O7:H4-A-ST93-CH11-31 (1); O9:H4-A-ST615-CH7-34 (1); O101:H10-A-ST617-CH11-negative (1); O153:H19-C-ST58-CH4-25 (1); O91:H28-B1-ST1196-CH6-31 (1); O2:HNM-B2-ST141-CH52-14 (1); **O16:H5-B2-ST131-CH40-41 (1)**; O77:H18-E-ST106-CH35-47 (1)
                                                                                   CTX-M-9 (1)                             **O25b:H4-B2-ST131-CH40-22 (1)**
                                                                                   SHV-12 (2)                              O68:H21-B1-ST602-CH19-86 (1); ONT:HNM-A-ST10-CH11-54 (1)
  2011        313                                26 (8.3%)                         CTX-M-15 (11)                           **O25b:H4-B2-ST131-CH40-30 (11)**
                                                                                   CTX-M-14 (8)                            O7:H4-A-ST93-CH11-31 (1); O8:H4-C-ST88-CH4-39 (1); O9:H4-A-ST609-CH7-0 (1); O11:H9-C-ST1615-CH263-32 (1); O8:H7-B1-ST1642-CH4-31 (1); O23:H28-B1-ST156-CH29-38 (1); O153:H34-F-ST354-CH88-58 (1); ONT:H34-F-ST354-CH88-58 (1)
                                                                                   CTX-M-1 (5)                             ONT:HNM-A-ST1630- CH11-400 (1); O9:H4-A-ST1421-CH7-54 (1); O54:H21-B1-ST58-CH4-0 (1); ONT:H25-B1-ST641-CH6-479 (1); O153:H15-E- ST973-CH187-27 (1)
                                                                                   SHV-12 (2)                              **O25b:H4-B2-ST131-CH40-22 (1)**; O2:HNM-F-ST648-CH4-58 (1)
  **Total**   **2.427**                          **96 (4.0%)**                                                             
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ESBL Enzymes {#S3.SS2}
------------

Of the 96 ESBL-EC isolates, 40 were positive for CTX-M-15, 36 for CTX-M-14, eight for CTX-M-1, and four for CTX-M-9, CTX-M-32, and SHV-12 each ([Figure 2](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}).

![Distribution of extended-spectrum β-lactamase (ESBL) enzymes. Of the 96 ESBL-EC bloodstream isolates, 40 were positive for CTX-M-15, 36 for CTX-M-14, eight for CTX-M-1, and four for CTX-M-9, CTX-M-32, and SHV-12 each.](fmicb-10-01530-g002){#F2}

Phylogenetic Groups {#S3.SS3}
-------------------

The commonest phylogenetic group was B2 (44 isolates), followed by B1 (18 isolates), A and E (11 isolates from each), F (six isolates), C (five isolates), and D (one isolate).

The majority of CTX-M-15-producing (87.5%, 35/40) isolates belonged to phylogenetic group B2. In contrast, only five (14%) of 36 CTX-M-14-producing isolates were assigned to this phylogenetic group (*P* \< 0.001) ([Table 1](#T1){ref-type="table"}).

Multilocus Sequence Types {#S3.SS4}
-------------------------

The 96 ESBL-EC isolates belonged to 36 different STs ([Table 1](#T1){ref-type="table"}). The commonest was ST131 (41 isolates), followed by ST58 (four isolates), ST354 (four isolates), ST393 (four isolates), ST405 (four isolates), and ST359 (three isolates). Most CTX-M-15 isolates (87.5%, 35/40) were ST131, whereas the CTX-M-14 isolates belonged to 23 different STs, none of which accounted for \>12% and only 3 (8.3%) of 36 isolates were ST131 ([Table 1](#T1){ref-type="table"}).

Clonotypes {#S3.SS5}
----------

CH typing identified 40 clonotypes, with CH40-30 being the most prevalent, which was present in 35 ST131 CTX-M-15-producing isolates. Other prevalent clonotypes were: CH41-35 (three ST359 isolates), CH40-22 (three ST131 isolates), CH106-54 (four ST393 isolates), CH37-27 (four ST405 isolates), and CH88-58 (four ST354 isolates) ([Table 1](#T1){ref-type="table"}).

Serotypes {#S3.SS6}
---------

The 96 ESBL-EC isolates belonged to 21 O serogroups and expressed 17 H flagellar antigens. However, 39 ST131 isolates belonged to serotype O25b:H4. Other prevalent serotypes were: O15:H1 (four ST393 isolates), O9:H4 (three CC46 isolates), O7:H4 (two ST93 isolates), O8:H7 (two ST1642 isolates), O101:H10 (two CC10 isolates), and O153:H34 (two ST354 isolates) ([Table 1](#T1){ref-type="table"}).

Virulence Genes {#S3.SS7}
---------------

The ST131 isolates showed a higher virulence score (range 11 to 21; mean 13.49) compared with the non-ST131 isolates (range 1 to 18; mean 8.31) (*P* \< 0.001).

Fourteen virulence genes (*afa/draBC*, *afaFM955459*, *yfcV*, *sat*, *cnf1*, *iucD*, *iutA*, *fyuA*, *chuA*, *kpsM II*, *kpsM II-K2*, *malX*, *usp*, and *ompT*) were significantly associated with ST131 isolates, whereas only five virulence genes (*fimAv*~MT78~, *hlyF*, *vat*, *iroN*, *cvaC*, *iss*, and *traT*) were significantly associated with non-ST131 isolates.

Of the 96 ESBL-EC isolates, 65.6% were classified as ExPEC and 44.8% classified as UPEC. The prevalence of ExPEC (97.6 vs. 41.8%) (*P* \< 0.001) and UPEC (90.2 vs. 10.9%) (*P* \< 0.001) status were higher within ST131 isolates than within non-ST131 isolates ([Table 2](#T2){ref-type="table"}).

###### 

Virulence genes in ST131 and non-ST131 bloodstream isolates.

  **Gene(s)**         **Comment**                                                                                                        **Total isolates (*n* = 96)**   **ST131 isolates (*n* = 41)**   **Non-ST13 isolates (*n* = 55)**   ***P*-value^a^ ST131 vs. non-ST131**
  ------------------- ------------------------------------------------------------------------------------------------------------------ ------------------------------- ------------------------------- ---------------------------------- --------------------------------------
  **Adhesins**                                                                                                                                                                                                                              
  *fimH*              D-mannose-specific adhesin, type 1 fimbriae                                                                        94 (97.9%)                      40 (97.6%)                      54 (98.1%)                         
  *fimAv*~*MT78*~     Fim A variant MT78 of type 1 fimbriae                                                                              10 (10.4%)                      0                               **10 (18.2%)**                     0.003
  *papAH*             P fimbriae operon. Major structural subunit                                                                        21 (21.9%)                      10 (24.4%)                      11 (20.0%)                         
  *papC*              P fimbriae operon. Pilus assembly                                                                                  21 (21.9%)                      10 (24.4%)                      11 (20.0%)                         
  *papEF*             P fimbriae operon. Minor tip pilins.                                                                               22 (22.9%)                      10 (24.4%)                      12 (21.8%)                         
  *papG I*            P fimbriae operon. Allele I of *papG* gene                                                                         0                               0                               0                                  
  *papG II*           P fimbriae operon. Allele II of *papG* gene                                                                        16 (16.7%)                      9 (22.0%)                       7 (12.7%)                          
  *papG III*          P fimbriae operon. Allele III of *papG* gene                                                                       2 (2.1%)                        1 (2.4%)                        1 (1.8%)                           
  *papG IV*           P fimbriae operon. Allele IV of *papG* gene                                                                        0                               0                               0                                  
  *sfa/focDE*         *Sfa* (S fimbriae) and *foc* (F1C fimbriae) operons                                                                1 (1.0%)                        0                               1 (1.8%)                           
  *afa/draBC*         Dr antigen-specific adhesin operons                                                                                27 (28.1%)                      **27 (65.9%)**                  0                                  \< 0.001
  *afaFM955459*       Operon afa specific for clone O25b-ST131                                                                           26 (27.1%)                      **26 (63.4%)**                  0                                  \< 0.001
  *yfcV*              Putative chaperone-usher fimbria                                                                                   49 (51.0%)                      **37 (90.2%)**                  12 (21.8%)                         \< 0.001
  **Toxins**                                                                                                                                                                                                                                
  *sat*               Secreted autotransporter toxin                                                                                     45 (46.9%)                      **37 (90.2%)**                  8 (14.5%)                          \< 0.001
  *cnf1*              Cytotoxic necrotizing factor 1                                                                                     4 (4.2%)                        **4 (9.8%)**                    0                                  0.030
  *hlyA*              α-hemolysin                                                                                                        5 (5.2%)                        4 (9.8%)                        1 (1.8%)                           
  *hlyF*              Hemolysin F                                                                                                        25 (26.0%)                      4 (9.8%)                        **21 (38.2%)**                     0.001
  *cdtB*              Cytolethal distending toxin                                                                                        1 (1.0%)                        1 (2.4%)                        0                                  
  *tsh*               Tsh (temperature-sensitive hemagglutinin) serine protease                                                          10 (10.4%)                      2 (4.9%)                        8 (14.5%)                          
  *vat*               Vacuolating autotransporter toxin. Serine protease                                                                 6 (6.3%)                        0                               **6 (10.9%)**                      0.031
  **Iron uptake**                                                                                                                                                                                                                           
  *iucD*              Ferric aerobactin receptor                                                                                         81 (84.4%)                      **41 (100%)**                   40 (72.7%)                         \< 0.001
  *iutA*              Ferric aerobactin receptor                                                                                         81 (84.4%)                      **41 (100%)**                   40 (72.7%)                         \< 0.001
  *iroN*              Catecholate (salmochelin) siderophore receptor                                                                     21 (21.9%)                      3 (7.3%)                        **18 (32.7%)**                     0.002
  *fyuA*              *Yersinia* siderophore receptor                                                                                    65 (67.7%)                      **41 (100%)**                   24 (43.6%)                         \< 0.001
  *chuA*              Heme binding outer membrane                                                                                        62 (64.6%)                      **41 (100%)**                   21 (38.2%)                         \< 0.001
  **Capsule**                                                                                                                                                                                                                               
  *kpsM II*           Group II capsule                                                                                                   60 (62.5%)                      **40 (97.6%)**                  20 (36.4%)                         \< 0.001
  *kpsM II-K2*        K2 variant of group II capsule                                                                                     27 (28.1%)                      **27 (65.9%)**                  0                                  \< 0.001
  *kpsM II-K5*        K5 variant of group II capsule                                                                                     29 (30.2%)                      11 (26.8%)                      18 (32.7%)                         
  *neuC-K1*           K1 antigen                                                                                                         4 (4.2%)                        2 (4.9%)                        2 (3.6%)                           
  *kpsM III:*         Group III capsule                                                                                                  3 (3.1%)                        0                               3 (5.5%)                           
  **Miscellaneous**                                                                                                                                                                                                                         
  *cvaC*              ColV (microcin V)                                                                                                  17 (17.7%)                      3 (7.3%)                        **14 (25.5%)**                     0.018
  *iss*               Increased serum survival (OMP)                                                                                     19 (19.8%)                      3 (7.3%)                        **16 (29.1%)**                     0.007
  *traT*              Serum resistance-associated (OMP)                                                                                  56 (58.3%)                      18 (43.9%)                      **38 (69.1%)**                     0.012
  *ibeA*              Invasion of brain endothelium                                                                                      9 (9.4%)                        3 (7.3%)                        6 (10.9%)                          
  *malX*              Pathogenicity-associated island marker (PAI)                                                                       55 (57.3%)                      **41 (100%)**                   14 (25.5%)                         \< 0.001
  *usp*               Uropathogenic-specific protein (bacteriocin)                                                                       48 (50.0%)                      **41 (100%)**                   7 (12.7%)                          \< 0.001
  *ompT*              Outer membrane protein (protease) T                                                                                70 (72.9%)                      **41 (100%)**                   29 (52.7%)                         \< 0.001
  **ExPEC status**    If positive for ≥2 of 5 markers, including *papAH* and/or *papC*, *sfa/focDE*, *afa/draBC*, *kpsM II* and *iutA*   63 (65.6%)                      **40 (97.6%)**                  23 (41.8%)                         \< 0.001
  **UPEC status**     If positive for ≥3 of 4 markers, including *chuA*, *fyuA*, *vat* and *yfcV*.                                       43 (44.8%)                      **37 (90.2%)**                  6 (10.9%)                          \< 0.001

a

P

-values were calculated using the Fisher's exact test and are shown where

P

\< 0.05. Significant differences are indicate in bold.

*H*30Rx Subclone and Virotypes of ST131 Isolates {#S3.SS8}
------------------------------------------------

The 35 ST131 O25b:H4 CTX-M-15-producing isolates belonged to the *H*30Rx subclone. Twenty-six of the 35 *H*30Rx isolates showed the virotype A, four isolates the virotype E and five isolates the virotype F. In contrast, the three isolates of *H*22 subclone showed the virotypes D2 (one isolate) and D4 (two isolates). Besides, one of the two isolates belonging to *H*41 subclone showed the virotype C3, while the other was non-typeable (NT).

In 2011, there was a very drastic change in the virotypes, due to the emergence of the virotypes E (*sat*, *papGII*, *cnf1*, *hlyA*, and *kpsMII-K5*) and F (*sat*, *papGII*, and *kpsMII-K5*) which have displaced the virotype A (*afa/draBC*, *afa* operon FM955459, *sat*, and *kpsMII-K2*). Thus 8 (66.7%) of the 12 ST131 isolates obtained in 2011 belonged to virotypes E and F vs. 1 (3.4%) of 29 ST131 isolates from 2006 to 2010 (*P* \< 0.001). By contrast, while in the first period 23 (79.3%) of 29 ST131 isolates belonged to virotype A in the last year represented only 3 (25%) of 12 isolates (*P* = 0.002) ([Figure 3](#F3){ref-type="fig"}).

![Distribution of subclones and virotypes of extended-spectrum β-lactamase-producing *E. coli* (ESBL-EC) ST131 bloodstream isolates. A drastic change in ST131 virotypes happened in 2011 due to the emergence of the virotypes E and F, which displaced virotype A.](fmicb-10-01530-g003){#F3}

Macrorestriction Profiles by PFGE {#S3.SS9}
---------------------------------

[Supplementary Figures S1, S2](#TS1){ref-type="supplementary-material"} show a dendrogram with the *XbaI* macrorestriction profiles of the ST131 and non-ST131 which showed a similarity of 61.3 and 50.2%, respectively. A high genetic diversity was detected among the 40 ST131 isolates, showing 31 different PFGE profiles. However, the isolates remained distributed within three virotype-specific clusters of 75% (four virotype E isolates), 84.2% (25 virotype A isolates) and 94.6% identity (five virotype F isolates). As expected, the 55 non-ST131 isolates showed even more heterogeneity, with 55 different profiles. However, the majority of isolates belonging to the same STs, clonotypes and O:H serotypes grouped together in the dendrogram.

Discussion {#S4}
==========

The management of BSIs due to *E. coli* has been complicated due to antimicrobial resistance emergence, especially since 2000. A low proportion of the bacteraemia *E. coli* isolates recovered in our hospital between 1989 and 1992 were resistant to extended-spectrum cephalosporins (ESC) (0.5%) and fluoroquinolones (FQs) (1%), and none of the 213 *E. coli* isolates was multidrug resistant (MDR). However, a significant number turned out to be resistant (ESC 8%, FQs 31%, and MDR 16%) within 614 bacteraemia *E. coli* isolates obtained between 2010 and 2011 (unpublished data).

*Escherichia coli* BSIs are increasing in Europe and worldwide mainly due to the increased resistance to antibiotics, and especially to the expansion of high-risk clones such as ST131 ([@B51]; [@B14]; [@B52]). Since 2006, it is evident that the prevalence of ESBL-EC has raised in our hospital. This increase has been due to the spread of the multidrug-resistant *H*30Rx subclone associated with the production of CTX-M-15. Thus, the number of ESBL-EC isolates increased from 1.0% during 2000--2005 to 5.5% during 2006--2011. While during the first period 0% of the ESBL-EC isolates belonged to *H*30Rx subclone, in the second period this subclone represented 39.8%. A similar situation has been reported in other hospitals worldwide. Specifically, in a centralized Canadian region (Calgary), [@B42] investigated the prevalence and molecular characteristics of ESBL-EC bloodstream isolates obtained from the year 2000 to 2010 and found that these isolates increased significantly in the last years of the study (2% during 2000--2006 vs. 8% during 2007--2010). ST131 was first described in 2001, and its prevalence remained stable until 2006. However, since 2007, the prevalence of ST131 isolates increased significantly. Like in our study, most isolates from Canada produced either CTX-M-15 or CTX-M-14 ([@B42]).

In the present study, while most of the 40 CTX-M-15-producing isolates belonged to ST131, the 36 CTX-M-14 positive isolates were distributed within 23 different STs. Similar results were observed by [@B34] who reported a prevalence of 9.2% (39/425) of ESBL-EC among isolates causing bacteraemia of urinary origin in eight Spanish hospitals during 2010 and 2011. Of the 39 ESBL-EC isolates, 21 produced CTX-M-15 and 11 CTX-M-14. Fifteen STs were identified, but as in our study, the ST131 *H*30Rx subclone was predominant among CTX-M-15 isolates (20 of 21 isolates). Another seven STs (ST69, ST156, ST359, ST405, ST410, ST453, and ST609) reported by [@B34] were also identified in the present study. However, the phylogroup distribution of our study differed from the one showed by [@B34]: A (11.5 vs. 7.7%), B1 (18.8 vs. 23.1%), B2 (45.8 vs. 53.8%), C (5.2 vs. 5.1%), D (1.0 vs. 10.3%), E (11.5 vs. 0%), and F (6.3 vs. 0%).

In our investigation, the CH typing identified 40 clonotypes, subdiving ST131 isolates in three subclones: CH40-30 (35 *H*30-Rx isolates of subclade C2), CH40-22 (three *H*22 isolates of clade B), and CH40-41 (two *H*41 isolates of clade A). Recently, [@B47] presented a new Web tool for CH typing. To determine the resolution of it, 243 *E. coli* isolates were analyzed. Those isolates were resistant to third-generation cephalosporins and obtained from Danish patients with BSIs. A total of 48 different STs were identified, with ST131 the most common (50.2% of isolates; 95 CH40-30, 14 CH40-27, 11 CH40-41, one CH40-22, and one CH40-35). In addition to ST131, other 15 STs (ST23, ST58, ST69, ST88, ST93, ST95, ST141, ST345, ST354, ST393, ST405, ST410, ST453, ST617, and ST648) were identified in both studies. Thus, 72.9% of the Spanish isolates presented the same STs as 72.8% of the Danish isolates. Besides, the majority of the Spanish and Danish bloodstream isolates of the same ST displayed as well the same clonotype. Also, many of the STs found among our isolates were identified within the ESBL-EC isolates collected from BSIs in Japan (ST10, ST23, ST58, ST69, ST93, ST95, ST131, ST156, ST354, ST362, ST393, ST405, ST602, and ST648) ([@B28]), in Korea (ST10, ST69, ST95, ST131, ST354, ST393, ST405, ST410, ST453, ST617, ST648, and ST1642) ([@B26]), and in China (ST10, ST23, ST58, ST69, ST95, ST131, ST393, ST405, ST410, ST602, ST617, ST648, and ST1642) ([@B53]).

In Japan and other Asian countries, the CTX-M-27-producing C1/*H*30R-M27 and CTX-M-14-producing C1/*H*30R-nM27 subclades are more frequently isolated than the CTX-M-15-producing C2/*H*30Rx subclade ([@B29]). We have not detected these two subclades within the collection of the study reported here (2000-2011). However, the epidemiologic situation seems to be changing in Spain since we have detected the subclade C1/*H*30R-M27 (five cases) within 92 ESBL-EC obtained from patients with urinary tract infections (84 cases) and other extraintestinal infections of our hospital in 2015, being the most frequent after the C2/*H*30Rx subclade (27 cases) ([@B16]).

The ST131 bloodstream isolates showed a higher virulence score than non-ST131 isolates. Furthermore, the prevalence of the ExPEC and UPEC status was also higher among the ST131 isolates than in the non-ST131 isolates, supporting the idea of a greater virulence potential of ST131, confirming the findings of previous studies ([@B5], [@B6]; [@B12]; [@B34]). However, the success of ST131 isolates cannot be explained exclusively by its high number of virulence genes. ST131 isolates are carriers of both virulence and resistance genes, which is very rare in classical extraintestinal pathogenic *E. coli* isolates ([@B38]). In addition, most ESBL-producing ST131 isolates are resistant to both extended-spectrum cephalosporins and fluoroquinolones ([@B11]; [@B24]). Diverse fitness cost associated with high-level resistance to fluoroquinolones was reported to contribute to the selection of the international clones of methicillin-resistant *Staphylococcus aureus*, *Clostridium difficile* ESBL-producing *Klebsiella pneumoniae* and *E. coli* ([@B17]). It is also important to highlight that the major reservoir of human extraintestinal pathogenic *E. coli* is the human digestive tract and that ST131 is the most competitive of the phylogenetic group B2 clones known to colonize the human digestive tract ([@B4]; [@B38]). Recently, [@B31] after analyzing the genome of 1,094 systematically sampled bacteremia ST131 isolates from the British Society for Antimicrobial Chemotherapy (BSAC) collection, found that clade C had accumulated a significantly elevated allelic diversity, particularly enriched for genes involved in anaerobic metabolism as well as other loci important for colonization of the human host by ExPEC.

In the present study, most of the isolates ST131 showed the virotype A. The international pulsotype L, which was responsible for the significant increase in BSIs in Calgary since 2007, also belonged to the virotype A and subclone *H*30Rx ([@B41]). However, in many countries, the virotype C is the most frequent among ESBL-EC isolates belonging to *H*30Rx subclone ([@B40]; [@B41]). The isolates of virotypes E and F obtained during the last year (2011) of our study may possibly represent new sublineages of the ST131 clonal group.

A high genetic diversity was detected by PFGE. However, the ST131 isolates grouped in three specific clusters of virotypes A, E, and F suggesting a clonal basis for the virotypes ([@B6]). In future studies it would be very interesting to determine the whole genome sequence of the ST131 isolates belonging to virotypes A, E and F to know if they really belong to different branches within the *H*30Rx C2 subclade.

In the present study we have not detected any carbapenem-resistant *E. coli*, but O25b:H4-ST131- *H*30-Rx isolates of virotype E and co-producing CTX-M-15 and OXA-48 were recently reported in another Spanish hospital (HUCA, Oviedo) near our region ([@B15]).

The present study has certain limitations such as it was performed in a single hospital, non-ESBL ST131 isolates were not included, lack of whole genome sequencing (WGS) analysis or the fact that the last isolates were obtained during 2011.

Conclusion {#S5}
==========

ST131 was the sequence type most frequently detected; moreover, the *H*30Rx subclone was responsible for the significant increase of ESBL-EC bloodstream isolates since 2006. In the year 2011 two new virotypes (E and F) of *H*30Rx subclone have emerged. Future molecular studies are needed to understand the dynamics of expansion of this successful high-risk subclone in order to prevent its spread and establish the importance of the two new virotypes.
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